-
Wells Fargo Upgrades Regulus Therapeutics (RGLS) to Overweight
-
Regulus Therapeutics (RGLS) Announces Successful Completion of its Phase 1b MAD Clinical Trial of Farabursen (RGLS8429) for the Treatment of ADPKD
-
H.C. Wainwright Reiterates Buy Rating on Regulus Therapeutics (RGLS)
-
Regulus Therapeutics (RGLS) Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen
-
Jones Trading Reiterates Buy Rating on Regulus Therapeutics (RGLS)
-
Regulus Therapeutics (RGLS) Misses Q3 EPS by 4c
-
H.C. Wainwright Reiterates Buy Rating on Regulus Therapeutics (RGLS)
-
Canaccord Genuity Reiterates Buy Rating on Regulus Therapeutics (RGLS)
-
Regulus Therapeutics (RGLS) Misses Q2 EPS by 5c
-
H.C. Wainwright Reiterates Buy Rating on Regulus Therapeutics (RGLS)
-
Regulus Therapeutics (RGLS) PT Raised to $10 at H.C. Wainwright
-
Jones Trading Reiterates Buy Rating on Regulus Therapeutics (RGLS)
-
Regulus Therapeutics (RGLS) Announces Positive Topline Data from Third Cohort in Phase 1b Trial of RGLS8429

